FindTrial
Sign In

Weekly maintainance therapy with Paclitaxel vs control arm after first line chemotherapy in patients with metastatic breast carcinoma. Phase III multicentric clinical trial.

Weekly maintainance therapy with Paclitaxel vs control arm after first line chemotherapy in patients with metastatic breast carcinoma. Phase III multicentric clinical trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2004-004031-59-IT
Enrollment
Unknown
Registered
2005-07-27
Start date
2004-11-22
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer MedDRA version: 6.1 Level: SOC Classification code 10038604

Interventions

Trade Name: TAXOL*100MG/17 ML IV1FL Product Name: NA Product Code: NA Pharmaceutical Form: Emulsion for infusion INN or Proposed INN: Paclitaxel CAS Number: 33069-62-4 Concentration unit: g gram(s) Co

Sponsors

AZIENDA OSPEDALIERA POLICLINICO DI MODENA
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Main Objective: ;Secondary Objective: ;Primary end point(s):—

Countries

Italy

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026